Citation & Authors
J Autoimmun. 2025;157:103493.
ABSTRACT · RESEARCH SUMMARY
Research summary
The matched TriNetX study found no significant difference in 7-year RA risk between GLP-1 receptor agonists and either DPP-4 inhibitors or basal insulin. SGLT2 inhibitors were associated with a lower RA risk than GLP-1 drugs (HR 0.88; 95% CI 0.80–0.96). This observational comparison is insufficient to support using glucose-lowering drugs as preventive treatment for RA.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
